Tuesday - April 14, 2026

Category Archives: Science

Adrenocortical Carcinoma Pipeline Outlook Report 2025: Insights Into Therapies, Research, and Market Potential

DelveInsight’s, “Adrenocortical Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Generalized Myasthenia Gravis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Generalized Myasthenia Gravis Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Generalized Myasthenia Gravis (gMG) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Alzheimer’s Disease Market Soars with FDA Approval of LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Treatment | DelveInsight

The Alzheimer’s disease market has achieved a groundbreaking milestone with the FDA approval of LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection for maintenance dosing in early Alzheimer’s disease treatment on August 15, 2025. Developed by Eisai Co., Ltd. and Biogen Inc., LEQEMBI … Continue reading →

Metastatic Uveal Melanoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Metastatic Uveal Melanoma Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Metastatic Uveal Melanoma pipeline landscape. It covers the Metastatic Uveal Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Dengue Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Dengue Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dengue therapeutics assessment … Continue reading →

Recurrent or Metastatic Head and Neck Cancer Pipeline Insights 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and … Continue reading →

Hemophilia B Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Hemophilia B Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hemophilia B pipeline landscape. It covers the Hemophilia B pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Migraine Pipeline Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Migraine Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics … Continue reading →

CRISPR Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR … Continue reading →

Pulmonary Arterial Hypertension Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Pulmonary Arterial Hypertension Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →